FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093818690> ?p ?o ?g. }

• W2093818690 endingPage "2816" @default.
• W2093818690 startingPage "2807" @default.
• W2093818690 abstract "BACKGROUND. Anemia occurs as a comorbidity in from 80% to 85% of patients with myelodysplastic syndromes (MDS): It causes fatigue, increases transfusion needs, and reduces quality of life. Darbepoetin α (DA) is an erythropoiesis-stimulating protein (ESP) that is more highly glycosylated and has a longer half-life relative to recombinant human erythropoietin (rHuEPO), thus, allowing less frequent administration, increased convenience, and better compliance. METHODS. This retrospective analysis included 81 patients with MDS who were enrolled at 9 Spanish centers and who received once-weekly, subcutaneous DA (75–300 μg) for 16 weeks. RESULTS. Fifty-five percent of all patients (38 of 69 evaluable patients) achieved responses; 30.4% of were major responses, and 24.6% were minor responses; 64.7% of rHuEPO-naive patients and 45.7% rHuEPO-treated patients responded; and 43.2% had received previous rHuEPO. Most responses (65.8%) occurred at or before Week 8. The median age at diagnosis was 70 years (range, 38–87 years), the median age at the initiation of DA treatment was 75 years (range, 39–91 years), and 56.8% of patients were women. The median time from last ESP dose to DA initiation was 16.8 weeks (range, 0.0–159.0 weeks; <1 week in 53.1% of patients). According to the French-American-British classification system (n = 81 patients), 39.5% had refractory anemia (RA), 46.9% had RA with ringed sideroblasts, 9.9% had RA with excess blasts (RAEB), 1.2% had RAEB in transformation, and 2.5% had chronic myelomonocytic leukemia. According to the International Prognostic Scoring System (n = 47 patients), 55.3% of patients were in the low-risk group, and 36.2% of patients were in the intermediate-1-risk group. The median baseline hemoglobin level was 8.9 g/dL (range, 8.4–9.1 g/dL). The Starting DA dose was 75 μg per week in 3.7% of patients, 150 μg per week in 65.4% of patients, and 300 μg per week in 29.6% of patients (the dose was increased in 18.5% of patients and reduced in 9.9% of patients; median time to dose adjustment, 8 weeks). Five patients received granulocyte colony-stimulating factors. No DA-related adverse reactions occurred. CONCLUSIONS. In the current study, 55% of evaluable patients with MDS safely achieved an erythroid response. Cancer 2006. © 2006 American Cancer Society." @default.
• W2093818690 created "2016-06-24" @default.
• W2093818690 creator A5010010012 @default.
• W2093818690 creator A5015674853 @default.
• W2093818690 creator A5030407146 @default.
• W2093818690 creator A5039737999 @default.
• W2093818690 creator A5054816508 @default.
• W2093818690 creator A5063059735 @default.
• W2093818690 creator A5073093146 @default.
• W2093818690 creator A5078746528 @default.
• W2093818690 creator A5087080626 @default.
• W2093818690 date "2006-01-01" @default.
• W2093818690 modified "2023-10-17" @default.
• W2093818690 title "Darbepoetin α for the treatment of anemia in patients with myelodysplastic syndromes" @default.
• W2093818690 cites W1541533982 @default.
• W2093818690 cites W187238933 @default.
• W2093818690 cites W1969313253 @default.
• W2093818690 cites W1970838494 @default.
• W2093818690 cites W1983781920 @default.
• W2093818690 cites W1984706919 @default.
• W2093818690 cites W1993317268 @default.
• W2093818690 cites W1993484356 @default.
• W2093818690 cites W1996092443 @default.
• W2093818690 cites W1996887331 @default.
• W2093818690 cites W2004089260 @default.
• W2093818690 cites W2010793812 @default.
• W2093818690 cites W2014903824 @default.
• W2093818690 cites W2022444634 @default.
• W2093818690 cites W2047858871 @default.
• W2093818690 cites W2048944977 @default.
• W2093818690 cites W2052480622 @default.
• W2093818690 cites W2052822682 @default.
• W2093818690 cites W2058820265 @default.
• W2093818690 cites W2063823548 @default.
• W2093818690 cites W2077411388 @default.
• W2093818690 cites W2080361105 @default.
• W2093818690 cites W2087211634 @default.
• W2093818690 cites W2102908631 @default.
• W2093818690 cites W2110949925 @default.
• W2093818690 cites W2132195012 @default.
• W2093818690 cites W2136976836 @default.
• W2093818690 cites W2137533808 @default.
• W2093818690 cites W2140639593 @default.
• W2093818690 cites W2140830841 @default.
• W2093818690 cites W2149982846 @default.
• W2093818690 cites W2157752127 @default.
• W2093818690 cites W2160058062 @default.
• W2093818690 cites W2170954997 @default.
• W2093818690 cites W2412900863 @default.
• W2093818690 cites W2538882843 @default.
• W2093818690 cites W4247972768 @default.
• W2093818690 cites W4253916874 @default.
• W2093818690 doi "https://doi.org/10.1002/cncr.22343" @default.
• W2093818690 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17115424" @default.
• W2093818690 hasPublicationYear "2006" @default.
• W2093818690 type Work @default.
• W2093818690 sameAs 2093818690 @default.
• W2093818690 citedByCount "36" @default.
• W2093818690 countsByYear W20938186902012 @default.
• W2093818690 countsByYear W20938186902013 @default.
• W2093818690 countsByYear W20938186902015 @default.
• W2093818690 countsByYear W20938186902018 @default.
• W2093818690 countsByYear W20938186902021 @default.
• W2093818690 crossrefType "journal-article" @default.
• W2093818690 hasAuthorship W2093818690A5010010012 @default.
• W2093818690 hasAuthorship W2093818690A5015674853 @default.
• W2093818690 hasAuthorship W2093818690A5030407146 @default.
• W2093818690 hasAuthorship W2093818690A5039737999 @default.
• W2093818690 hasAuthorship W2093818690A5054816508 @default.
• W2093818690 hasAuthorship W2093818690A5063059735 @default.
• W2093818690 hasAuthorship W2093818690A5073093146 @default.
• W2093818690 hasAuthorship W2093818690A5078746528 @default.
• W2093818690 hasAuthorship W2093818690A5087080626 @default.
• W2093818690 hasBestOaLocation W20938186901 @default.
• W2093818690 hasConcept C121332964 @default.
• W2093818690 hasConcept C126322002 @default.
• W2093818690 hasConcept C141071460 @default.
• W2093818690 hasConcept C142424586 @default.
• W2093818690 hasConcept C2777928532 @default.
• W2093818690 hasConcept C2778248108 @default.
• W2093818690 hasConcept C2778534260 @default.
• W2093818690 hasConcept C2780007613 @default.
• W2093818690 hasConcept C2780240888 @default.
• W2093818690 hasConcept C2780817109 @default.
• W2093818690 hasConcept C2781404941 @default.
• W2093818690 hasConcept C71924100 @default.
• W2093818690 hasConcept C87355193 @default.
• W2093818690 hasConcept C90924648 @default.
• W2093818690 hasConceptScore W2093818690C121332964 @default.
• W2093818690 hasConceptScore W2093818690C126322002 @default.
• W2093818690 hasConceptScore W2093818690C141071460 @default.
• W2093818690 hasConceptScore W2093818690C142424586 @default.
• W2093818690 hasConceptScore W2093818690C2777928532 @default.
• W2093818690 hasConceptScore W2093818690C2778248108 @default.
• W2093818690 hasConceptScore W2093818690C2778534260 @default.
• W2093818690 hasConceptScore W2093818690C2780007613 @default.
• W2093818690 hasConceptScore W2093818690C2780240888 @default.
• W2093818690 hasConceptScore W2093818690C2780817109 @default.

• next